Proceedings of a conference sponsored by the Societal Institute of the Mathematical Sciences (the 14th in a series of research application conferences begun in 1974) held in July, 1998, in Divonne-les-Bains, France.

Includes bibliographical references and index.

Machine generated contents note: Part I: Evaluating HIV Prevention Programs: Context and Concepts -- Chapter 1. Overview of HIV Prevention Programs in Developing Countries Michael H. Merson andJulia M. Dayton 13 -- Chapter 2. Implications of Economic Evaluations for National HIV Prevention Policy Makers David R. Holtgrave -- and Steven D. Pinkerton 32 -- Chapter 3. Statistical Issues in HIV Prevention Ron Brookmeyer 55 -- Chapter 4. Epidemiological Issues in the Evaluation of HIV Prevention Programs Nancy S. Padian and Stephen C. Shiboski 79 -- Part II: Cost-Effectiveness and Resource Allocation -- Chapter 5. Difficult Choices, Urgent Needs: Optimal Investment in HIV Prevention Programs Margaret L. Brandeau 97 Chapter 6. Methadone Treatment as HIV Prevention: Cost-EffectivenessAnalysis Harold Pollack 118 -- Chapter 7. Costs and Benefits of Imperfect HIV Vaccines: Implications for Vaccine Development and Use Douglas K Owens, Donna M. Edwards, and Ross D. Shachter 143 -- Part III: Case Studies -- Chapter 8. Harm Reduction in Rome: A Model-Based Evaluation of Its Impact on the HIV-1 Epidemic MassimoArca, Teresa Spadea, Giulia Cesaroni, Marina Davoli, Annette D. Verster, and Carlo A. Perucci 175 -- Chapter 9. Evaluating Israel's Ethiopian Blood Ban EdwardH. Kaplan 189 -- Chapter 10. Feeding Strategies for Children of HIV-Infected Mothers: Modeling the Trade-Off Between HIV Infection and Non-HIV Mortality James G. Kahn, ElliotMarseille, and Joseph Saba 202 -- Part IV: New Methods for New Problems -- Chapter 11. Design of HIVTrials for Estimating External Effects Tomas Philipson 223 -- Chapter 12. Estimation of Vaccine Efficacy for Prophylactic HIV Vaccines Ira M Longini, Jr., Michael G. Hudgens, and M. Elizabeth Halloran 241 -- Chapter 13. Health Policy Modeling: Epidemic Control, HIVVaccines, and -- Risky Behavior Sally Blower, Katia Koelle,and John Mills 260 -- Chapter 14. Development and Validation of a Serologic Testing Algorithm for Recent HIV Seroconversion GlenA. Satten, -- Robert S. Janssen, Susan Stramer, and Michael P Busch 290 -- Chapter 15. Issues in Quantitative Evaluation of Epidemiologic Evidence for Temporal Variability of HIV Infectivity Stephen C. Shiboski and Nancy S. -- Padian 305.

Electronic reproduction. Palo Alto, Calif. : ebrary, 2009. Available via World Wide Web. Access may be limited to ebrary affiliated libraries.